Kimball AS, Davis FM, denDekker A, Joshi AD, Schaller MA, Bermick J, et al
Ozempic (semaglutide) and other glucagon-like peptide-1 (GLP-1) receptor agonist medications target underlying issues that drive weight gain during menopause, such as insulin resistance and metabolic shifts, explains endocrinologist and obesity specialist Alex Watson, M.D
Does not contain: No added dairy, egg, peanut, tree nut, fish, shellfish, soy, wheat, gluten, yeast, or sesame ingredients
Patients changed from polytherapy to monotherapy also may demonstrate improvement in cognition
Patients should not rush dose increases and should communicate with their prescribers if side effects are limiting their ability to maintain adequate nutrition or physical activity